Trials / Completed
CompletedNCT00561392
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and efficacy of 10 cm\^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm\^2 for at least 8 weeks. This proportion was then compared to historical data of the percentage of patients who could reach a rivastigmine capsule target dose of 12 mg and stay on it at least 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine 5 and 10 cm^2 patch |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-11-21
- Last updated
- 2012-04-16
- Results posted
- 2011-03-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00561392. Inclusion in this directory is not an endorsement.